Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade.

被引：0
|
作者：
Diefenbach, Catherine S. Magid
Hong, Fangxin
Ambinder, Richard F.
Cohen, Jonathon Brett
David, Kevin Andrew
Advani, Ranjana H.
Robertson, Michael J.
Fenske, Timothy S.
Barta, Stefan K.
Palmisano, Neal
Svoboda, Jakub
Morgan, David S.
Karmali, Reem
Kahl, Brad
Ansell, Stephen M.
机构：
[1] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[2] Harvard Univ, Boston, MA USA
[3] Bunting Blaustein Canc Res Bldg, Baltimore, MD USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[5] Canc Inst New Jersey, New Brunswick, NJ USA
[6] Stanford Canc Inst, Stanford, CA USA
[7] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA
[8] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI USA
[9] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[10] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
[11] Univ Penn, Philadelphia, PA 19104 USA
[12] Vanderbilt Univ Sch Med, Nashville, TN USA
[13] Northwestern Univ, Chicago, IL 60611 USA
[14] Washington Univ, Sch Med, St Louis, MO USA
[15] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7538
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade.
    Santomasso, Bianca
    Haggiagi, Aya
    Malani, Rachna
    Maher, Colleen Anne
    Holder, Jenessa N.
    Shames, Yelena
    Wilcox, Jessica
    Flynn, Jessica
    Briggs, Samuel
    Panageas, Katherine
    Callahan, Margaret K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Subsets of interferon signaling and response to immune checkpoint blockade.
    Lee, Daniel
    Horowitch, Brooke
    Ding, Min
    Martinez-Morilla, Sandra
    Aung, Thazin Nwe
    Ouerghi, Feriel
    Wang, Xueting
    Wei, Wei
    Damsky, William
    Sznol, Mario
    Kluger, Harriet M.
    Rimm, David L.
    Ishizuka, Jeffrey Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Bone metastasis as an independent prognostic factor for survival in patients with advanced melanoma treated with immune checkpoint blockade.
    Teixeira, Marcos Rezende
    De Barros E Silva, Milton Jos
    Pandolfi, Natasha Carvalho
    Calsavara, Vinicius Fernando
    Oliveira, Thiago Bueno
    Tavares, Monique Celeste
    Rinck, Jose Augusto
    Garcia, Daniel
    Lima, Joao Paulo S. N.
    Duprat, Joao
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Immune-active microenvironment in SCCOHT: Rationale for therapy with immune checkpoint blockade.
    Van Oudenhove, Elke
    Jelinic, Petar
    Ricca, Jacob
    Narciso, Olvera
    Merghoub, Taha
    Levine, Douglas A.
    Zamarin, Dmitriy
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 95 - 95
  • [5] The prognostic impact of immune-related adverse events in real-world patients with metastatic melanoma treated with single-agent and combination immune checkpoint blockade.
    Watson, Alexander
    Goutam, Siddhartha
    Stukalin, Igor
    Ewanchuk, Benjamin
    Sander, Michael
    Meyers, Daniel E.
    Pabani, Aliyah
    Cheung, Winson Y.
    Heng, Daniel Yick Chin
    Cheng, Tina
    Monzon, Jose Gerard
    Navani, Vishal
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Epigenetic changes in T cells in response to immune checkpoint blockade.
    Goswami, Sangeeta
    Zhao, Hao
    Zhang, Xuejun
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Microsatellite instability in prostate cancer and response to immune checkpoint blockade.
    Abida, Wassim
    Cheng, Michael L.
    Armenia, Joshua
    Middha, Sumit
    Autio, Karen A.
    Rathkopf, Dana E.
    Morris, Michael J.
    Danila, Daniel Costin
    Slovin, Susan F.
    Carbone, Emily
    Hullings, Melanie
    Hechtman, Jaclyn Frances
    Reuter, Victor E.
    Berger, Michael F.
    Kantoff, Philip W.
    Sawyers, Charles L.
    Schultz, Nikolaus
    Solit, David B.
    Gopalan, Anuradha
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] HIV-positive Kaposi sarcoma and immune checkpoint blockade.
    Galanina, Natalie
    Goodman, Aaron
    Cohen, Philip R.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [9] The Role of Radiotherapy in Patients with Refractory Hodgkin Lymphoma after Brentuximab Vedotin and -/or Immune Checkpoint Inhibitors
    Zhao, R.
    Shao, H.
    Shi, G.
    Qiu, Y.
    Tang, T.
    Lin, Y.
    Chen, S.
    Huang, C.
    Liao, S.
    Chen, J.
    Fu, H.
    Liu, J.
    Shen, J.
    Liu, T.
    Xu, B.
    Zhang, Y.
    Yang, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E499 - E499
  • [10] The Role of Radiotherapy in Patients with Refractory Hodgkin Lymphoma after Brentuximab Vedotin and -/or Immune Checkpoint Inhibitors
    Liu, Ting-Bo
    Li, Xiaofan
    Zhao, Rui-Zhi
    Shao, Han
    Shi, Gui-Qing
    Qiu, Yan-Yan
    Tang, Tian-Lan
    Lin, Yu-Ping
    Chen, Si-Lin
    Huang, Cheng
    Liao, Si-Qin
    Chen, Jin-Hua
    Fu, Hai-Ying
    Liu, Jian-Zhi
    Shen, Jian-Zhen
    Xu, Ben-Hua
    Zhang, Yu-jing
    Yang, Yong
    BLOOD, 2023, 142
12345